Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 7/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702244 | 0.93 | RXFP1 (0.37) | TP53MAPTPPARGKMT2ASMN1; SMN2 | |
| SCHEMBL6704678 | 0.88 | MAPT (0.39) | TP53MAPTPPARGKMT2ASMN1; SMN2 | |
| SCHEMBL7688738 | 0.87 | MEN1 (0.46) | F10KMT2A | |
| SCHEMBL6699872 | 0.86 | PTGDR2 (0.36) | TP53MAPTPPARGKMT2ASMN1; SMN2 | |
| SCHEMBL6703652 | 0.84 | MEN1 (0.38) | TP53MAPTF10KMT2ASMN1; SMN2 | |
| SCHEMBL7679713 | 0.82 | MEN1 (0.40) | F10KMT2A | |
| SCHEMBL6705251 | 0.81 | SAE1 (0.34) | TP53MAPTPPARG | |
| SCHEMBL7679774 | 0.81 | SAE1 (0.35) | TP53F10KMT2ATRPV4 | |
| SCHEMBL6704409 | 0.81 | MAPT (0.32) | TP53MAPTF10KMT2AHTT | |
| SCHEMBL6703993 | 0.81 | MAPT (0.42) | TP53MAPTKMT2ASMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380230-B1 | FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-04-30 | — | — | US | disclosed |